Division of Pulmonary and Critical Care Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8550, USA.
Heart Fail Clin. 2012 Jul;8(3):461-74. doi: 10.1016/j.hfc.2012.04.010.
The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.
肺实质疾病相关肺动脉高压（PH）的病理生理学部分与低氧性肺血管收缩有关。这些患者的 PH 治疗存在争议。本文重点介绍了 III 型 PH，即肺疾病和/或缺氧所致 PH。III 型包括慢性阻塞性肺疾病和间质性肺疾病，这是最常见的与 PH 相关的肺实质疾病。它还包括由任何原因引起的睡眠呼吸紊乱和通气不足。其他与 PH 相关的肺实质疾病，如结节病和系统性血管炎（V 型），也进行了讨论。回顾了描述特定肺实质疾病中 PH 的数据。
